An estimated 196 million people globally suffer from age-related macular degeneration (AMD), with about 5.3% having moderate or severe distance vision impairment or blindness.[5]Deng Y, Qiao L, Du M, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022 Jan;9(1):62-79.
https://www.sciencedirect.com/science/article/pii/S2352304221000295
http://www.ncbi.nlm.nih.gov/pubmed/35005108?tool=bestpractice.com
Of the global 33.6 million adults aged 50 years and older who were blind in 2020, 1.8 million had AMD.[6]GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e130-43.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30425-3/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/33275950?tool=bestpractice.com
[7]GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e144-60.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30489-7/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/33275949?tool=bestpractice.com
Due to population ageing, the number of AMD patients is expected to increase annually.[5]Deng Y, Qiao L, Du M, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022 Jan;9(1):62-79.
https://www.sciencedirect.com/science/article/pii/S2352304221000295
http://www.ncbi.nlm.nih.gov/pubmed/35005108?tool=bestpractice.com
AMD is more prevalent in Europe (18.3%) and North America (14.3%) than in Asia (6.9%).[8]Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106-16.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70145-1/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/25104651?tool=bestpractice.com
Although rates do not appear to differ by sex, they do differ by ethnicity. For example, prevalence of AMD among people of European ancestry (12.3%) is greater than that reported in people of African ancestry (7.5%) and Asian ancestry (7.4%). Europeans have a higher prevalence of the geographic atrophy subtype (1.11%) than either African (0.14%), Asian (0.21%), or Hispanic (0.16%) populations.[8]Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106-16.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70145-1/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/25104651?tool=bestpractice.com